Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

Prior treatment

• Received or planned thrombolysis or endovascular therapy after onset.

Other illness

• Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.
• Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )
• With cancers or uncontrolled diabetes.
• Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset.
• Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination.
• With a history of alcohol or drug abuse or drug dependence.
• Those known to be allergic to the investigated drug or its components.

Lab values

• Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \> 2.5 times the upper limit of normal value, serum creatinine \> 1.5 times the upper limit of normal value)

Other

• NIHSS Ⅰa ≥2.
• The expected survival time is less than 3 months.
• Pregnancy, potential pregnancy, or breastfeeding.
• Currently participating in other clinical trials during the past 3 months.
• Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.

• Inpatients diagnosed with acute ischemic stroke.
• Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome.
• Acute ischemic stroke within 7 days after onset.
• 6 ≤ NIHSS \<20.
• Aged 18-70 years, male or female.
• The patient or representative has signed informed consent.